112 214

Cited 0 times in

Phosphodiesterase-5 Inhibitor Use in Robot Assisted Radical Prostatectomy Patients Is Associated with Reduced Risk of Death: A Propensity Score Matched Analysis of 1,058 Patients

DC Field Value Language
dc.contributor.author이광석-
dc.contributor.author이종수-
dc.contributor.author장원식-
dc.contributor.author최영득-
dc.contributor.author한현호-
dc.contributor.author허지은-
dc.date.accessioned2023-07-12T03:02:25Z-
dc.date.available2023-07-12T03:02:25Z-
dc.date.issued2023-01-
dc.identifier.issn2287-4208-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/195480-
dc.description.abstractPurpose: We investigated whether the use of a phosphodiesterase-5 inhibitor (PDE5i) after robot assited radical prostatectomy has a survival benefit over non-use patients because there are controversial results on the association between PDE5i use and survival outcomes for prostate cancer patients in literature. Materials and methods: We designed a retrospective, matched, large-sample cohort study of 5,545 patients who underwent robot assisted radical prostatectomy (RARP) during 2013-2021 in a single institute. The exclusion criteria was patients who were aged >70 years at surgery, American Society of Anesthesiologists (ASA) physical status classification grade 4 or 5, history of other malignancies, patients who started PDE5i 6 months after survery and patients with follow up period less than 24 months after surgery. Among the 1,843 included patients, 1,298 were PDE5i users, and 545 were PDE5i non-users. We performed propensity score matching (PSM) of PDE5i users (n=529) with non-users (n=529) by adjusting for the variables of age, Gleason grade group, pathological T stage, preoperative ASA physical status grade, and International Index of Erectile Function score. Results: There were no significant difference in patient characteristics according to PSM. Kaplan-Meier curve revealed the difference of overall survival for PDE5i users and non-users (clustered log-rank test p<0.05). In a stratified Cox regression analysis, PDE5i use after RARP was associated with improved overall survival and reduced risk of death (hazard ratio 0.43; confidence interval 0.24-0.79; p=0.007). The limitation of this study was that the indication for the prescription of PDE5i was not given. Conclusions: PDE5i administration after RARP were associated with overall survival of patients with prostate cancer. A further randomized control trial may reveal whether routine use of PDE5i after prostatectomy can improve survival of prostate cancer patient.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisher대한남성과학회-
dc.relation.isPartOfWORLD JOURNAL OF MENS HEALTH-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titlePhosphodiesterase-5 Inhibitor Use in Robot Assisted Radical Prostatectomy Patients Is Associated with Reduced Risk of Death: A Propensity Score Matched Analysis of 1,058 Patients-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorJongsoo Lee-
dc.contributor.googleauthorHye Rim Kim-
dc.contributor.googleauthorJi Eun Heo-
dc.contributor.googleauthorWon Sik Jang-
dc.contributor.googleauthorKwang Suk Lee-
dc.contributor.googleauthorSung Ku Kang-
dc.contributor.googleauthorHyunho Han-
dc.contributor.googleauthorYoung Deuk Choi-
dc.identifier.doi10.5534/wjmh.220063-
dc.contributor.localIdA02668-
dc.contributor.localIdA05500-
dc.contributor.localIdA05268-
dc.contributor.localIdA04111-
dc.contributor.localIdA04333-
dc.contributor.localIdA05531-
dc.relation.journalcodeJ02798-
dc.identifier.eissn2287-4690-
dc.identifier.pmid36649919-
dc.subject.keywordErectile dysfunction-
dc.subject.keywordPhosphodiesterase 5 inhibitors-
dc.subject.keywordProstatectomy-
dc.subject.keywordProstatic neoplasms-
dc.subject.keywordSurvival-
dc.contributor.alternativeNameLee, Kwang Suk-
dc.contributor.affiliatedAuthor이광석-
dc.contributor.affiliatedAuthor이종수-
dc.contributor.affiliatedAuthor장원식-
dc.contributor.affiliatedAuthor최영득-
dc.contributor.affiliatedAuthor한현호-
dc.contributor.affiliatedAuthor허지은-
dc.citation.volume41-
dc.citation.startPagee14-
dc.identifier.bibliographicCitationWORLD JOURNAL OF MENS HEALTH, Vol.41 : e14, 2023-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.